Antibody Therapeutics for Life

Notices

Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial at ASCO 2017 Annual Meeting in Chicago on June 2-6, 2017.
  • Written by Admin
  • Written date 2019-01-14 11:26:25
  • Inquire 1668

Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial

at ASCO 2017 Annual Meeting in Chicago on June 2-6, 2017.

 

https://am.asco.org/

List





Prev Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present PharmAbcine`s R&D prog...
Next Dr. Jin-San Yoo, CEO of PharmAbcine is presenting PharmAbcine`s R&D progress and...